Toxicity and efficacy of lenvatinib plus pembrolizumab in advanced endometrial cancer: a real-world retrospective analysis.

Front Oncol · 2025 · PMC12450652 · PMID 40989693

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

We observed a clear trend to initiate lenvatinib at a reduced dose, with only 14.1% of patients receiving the full 20 mg, regardless of ECOG performance status.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.